
Leukemia/medlineplus.gov
Mar 5, 2025, 08:16
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a paper Jennifer R. Brown and colleagues authored on X:
“AMPLIFY Ph 3 trial
867 patients, median age 61 yrs, ND CLL
No TP53/del17p, unmutated IGHV 59%
Acala+Ven x1 yr (AV) AV x1 yr + Obin x6 mo (AVO) Chemo-immunotherapy (CT)
3-year PFS: 77% AV versus 83% AVO versus 67% CT.”
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Authors: Jennifer R. Brown et al.
acalabrutinib
Alan Skarbnik
Alessandra Tedeschi
Andrew Aw
Arnon Philip Kater
Árpád Illés
Barbara Eichhorst
cancer
Carolyn Owen
Chronic lymphocytic leukemia (CLL)
Daniel Lysak
Jennifer R. Brown
John F. Seymour
Kara Miller
Ki-Seong Eom
Malgorzata Wach
Marianne de Borja
Martin Šimkovič
Miguel Arturo Pavlovsky
OncoDaily
Oncology
Paolo Ghia
Ting Yu
Veerendra Munugalavadla
Wojciech Jurczak
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 5, 2025, 07:48